Alnylam Pharma(GB:0HD2)
$147.38-1.95 (-1.31%)
GB:0HD2
Alnylam Pharma earnings date
$147.38
At close:-1.95 (-1.31%)
Alnylam Pharma (0HD2) Q2 2026 Earnings Report
4 Followers
GB:0HD2 Q2 2026 EPS Results
- Actual EPS
- $1.21
- Consensus EPS
- $1.63
- Beat/Miss
- Missed by -$0.42
- One Year Ago EPS
- -$0.51
GB:0HD2 Q2 2026 Revenue Results
- Actual Revenue
- $1.29B
- Expected Revenue
- $1.32B
- Beat/Miss
- Missed by -$31.18M
- YoY Revenue Growth
- +66.86%
Earnings Announcement Details
- Quarter
- Q2 2026
- Date
- 07/30/2026
- Time
- Before Open
- Conference Call
- Thursday, July 30, 2026
GB:0HD2 Upcoming Earnings
Alnylam Pharma's next earnings date is estimated for February 18, 2027, based on past reporting schedules.
Q2 2026 Earnings Call Audio
GB:0HD2 Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
Q2 2026 Earnings Call Summary
No earnings call summary is available for this earnings event.
GB:0HD2 Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Feb 18, 2027 | 2026 (Q4) | 1.72- | 0.82 | ― | ― |
| Oct 29, 2026 | 2026 (Q3) | 1.6615.72 | 1.84 | 754.35% (+13.88) | |
| Jul 30, 2026 | 2026 (Q2) | 1.631.21 | -0.51 | 337.25% (+1.72) | |
| Apr 30, 2026 | 2026 (Q1) | 0.871.51 | -0.44 | 443.18% (+1.95) | |
| Feb 12, 2026 | 2025 (Q4) | 1.150.82 | -0.65 | 226.15% (+1.47) | |
| Oct 30, 2025 | 2025 (Q3) | 0.561.84 | -0.87 | 311.49% (+2.71) | |
| Jul 31, 2025 | 2025 (Q2) | -0.54-0.51 | -0.13 | -292.31% (-0.38) | |
| May 01, 2025 | 2025 (Q1) | -0.89-0.44 | -0.52 | 15.38% (+0.08) | |
| Feb 13, 2025 | 2024 (Q4) | -0.59-0.65 | -1.1 | 40.91% (+0.45) | |
| Oct 31, 2024 | 2024 (Q3) | -0.92-0.87 | 1.15 | -175.65% (-2.02) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat Missed

